Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 3/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | IKBKB | O14920 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8410253 | 0.86 | USP1 (0.43) | DRD2DRD3HTR2CHTR2AKCNH2 | |
| SCHEMBL9310414 | 0.81 | HTR2C (0.65) | DRD2DRD3HTR2CHTR2AIKBKB | |
| SCHEMBL22132285 | 0.81 | HTR2C (0.65) | DRD2DRD3HTR2CHTR2AIKBKB | |
| SCHEMBL15830018 | 0.80 | PRMT5 (0.46) | IKBKB | |
| SCHEMBL17308285 | 0.80 | KEAP1 (0.47) | — | |
| SCHEMBL31229874 | 0.80 | HTR2C (0.62) | HTR2CHTR2A | |
| SCHEMBL15830285 | 0.80 | HTR2C (0.62) | HTR2CHTR2A | |
| SCHEMBL17303551 | 0.80 | HTR2C (0.62) | HTR2CHTR2A | |
| SCHEMBL3644759 | 0.80 | HTR2C (0.62) | HTR2CHTR2A | |
| SCHEMBL23469324 | 0.79 | HTR2A (0.48) | DRD2DRD3HTR2CHTR2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1891021-B1 | ASPARTYL PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-01-23 | — | — | EP | disclosed |
| EP-3287441-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-28 | — | — | EP | disclosed |
| US-8629155-B2 | Aspartyl protease inhibitors | MERCK SHARP & DOHME, CORP. (US) | 2014-01-14 | — | — | US | disclosed |
| US-8557798-B2 | Macrocyclic heterocyclic aspartyl protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8168641-B2 | Aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2012-05-01 | — | — | US | disclosed |
| US-8093254-B2 | Aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2012-01-10 | — | — | US | disclosed |
| US-7763606-B2 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2010-07-27 | — | — | US | disclosed |
| US-20100069406-A1 | ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100063121-A1 | Macrocyclic Heterocyclic Aspartyl Protease Inhibitors | SCHERING CORPORATION | 2010-03-11 | — | — | US | disclosed |
| US-20100016341-A1 | ASPARTYL PROTEASE INHIBITORS CONTAINING A TRICYCLIC RING SYSTEM | SCHERING CORPORATION | 2010-01-21 | — | — | US | disclosed |
| US-20070287692-A1 | ASPARTYL PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2007-12-13 | — | — | US | disclosed |
| US-20070099898-A1 | Heterocyclic aspartyl protease inhibitors | MERCK SHARP & DOHME LLC | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099898-A1 | Heterocyclic aspartyl protease inhibitors | CHRM1, ACHE, CHRM2 | DRD2 896/4885DRD3 692/4885HTR2C 642/4885 |
| US-20100063121-A1 | Macrocyclic Heterocyclic Aspartyl Protease Inhibitors | CHRM1, CHRM2, CHRM5 | DRD2 748/4885DRD3 353/4885HTR2C 1191/4885 |
| US-20100016341-A1 | ASPARTYL PROTEASE INHIBITORS CONTAINING A TRICYCLIC RING SYSTEM | PRSS1, PRSS3, BACE1 | DRD2 2907/4885DRD3 1754/4885HTR2C 2496/4885 |
| US-20070287692-A1 | ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, BACE1 | DRD2 1342/4885DRD3 866/4885HTR2C 2277/4885 |
| US-20100069406-A1 | ASPARTYL PROTEASE INHIBITORS | BACE1, CHRM1, CHRM2 | DRD2 1550/4885DRD3 889/4885HTR2C 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.